Browsing Tag

New Test FY21

Chemistry, General Information

Test Update: Thyroglobulin Antibody

Effective immediately, Thyroglobulin Antibody will be performed at Spectrum Health Reference Laboratory (SHRL, Grand Rapids, MI) and will no longer be a sendout to Mayo Clinical Laboratories. Collection instructions and other information may have changed, please visit the lab catalog for more information.

Thyroglobulin Tumor Marker will continue to be a sendout. If a Thyroglobulin Antibody is ordered with a Thyroglobulin Tumor Marker, then the Thyroglobulin Antibody will automatically be canceled as Mayo Clinic Laboratories will perform the Thyroglobulin Antibody as well as the Tumor Marker.

For questions and inquiries, please use the “Contact Us” link above.

 

TEST INFORMATION

New test: Thyroglobulin Antibody [LAB1230840] 

Former test: Thyroglobulin Antibody, Serum [LAB1230457]

Mentioned Test: Thyroglobulin, Tumor Marker, Serum [LAB864]

General Information, Test Spotlight

LIVE Webinar – NEW Colorectal Cancer Screen—Polymedco FIT Kit

Please join us for a 30-minute webinar on our new test for colorectal cancer screening: Occult Blood, CRC Screening.

The Fecal Immunochemical Test (FIT) screening method for hemoglobin in stool is the new standard of care for the early detection of blood which may be associated with colorectal cancer. It is changing the outcome of colorectal cancer.

We are offering two training webinars for our Spectrum Health and SHMG Providers and clinical staff on October 13th and 14th and two for our community providers and clinical staff (non-SHMG) on October 20th and 21st to help provide specific ordering practices.

The goal of this webinar is to address:

♦ Why screening for colorectal cancer is important.

♦ How to order to get supplies of the kit in your office.

♦ How to place the order.

♦ What is in the Polymedco FIT Kit.

♦ Patient collection process.

♦ Important instructions for the patient.

If you cannot attend one of the below webinars or have any questions, please use the Contact Us link above.

Continue Reading

Hemostasis/Coagulation

New Test: Factor VIII Chromogenic Assay

Effective July 1, 2021, the Coagulation Department within the Spectrum Health Regional Laboratory will go live with an in-house, bovine based, Chromogenic Factor VIII assay.

This assay, a photometric determination of Factor VIII activity, is useful for monitoring coagulation factor replacement therapy of selected extended half-life coagulation factor replacements and Emicizumab therapy, a recombinant, monoclonal antibody that restores the function of the missing activated factor VIII by bridging FIXa and FX. The action of Emicizumab interferes with all APTT clot based and human chromogenic based assays, leading to an overestimation of Factor VIII activity.  As such, the bovine based Chromogenic Factor VIII assay is recommended.  The Chromogenic Factor VIII activity also assists in the diagnosis of hemophilia A using a 2-stage assay, particularly when the 1-stage clot based assay is normal.

For questions about this test, please refer to the laboratory catalog or use the Contact Us link above.

TEST INFORMATION

Chromogenic Factor VIII Activity – Epic Code: LAB1230831 | Interface Code: 1230831 | CPT: 85240